Tuberculosis and Legionella pneumophila pneumonia in a patient receiving anti-tumour necrosis factor-alpha (anti-TNF-alpha) treatment.
Mancini
G
G
Erario
L
L
Gianfreda
R
R
Oliva
A
A
Massetti
A P
AP
Mastroianni
C M
CM
Vullo
V
V
D000328:Adult; D000893:Anti-Inflammatory Agents / Q000009:adverse effects* / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000009:adverse effects* / Q000627:therapeutic use; D001528:Behcet Syndrome / Q000188:drug therapy* / Q000276:immunology; D006801:Humans; D000069285:Infliximab; D007877:Legionnaires' Disease / Q000276:immunology / Q000382:microbiology; D008297:Male; D014397:Tuberculosis, Pulmonary / Q000276:immunology / Q000382:microbiology; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors*
D000893:Anti-Inflammatory Agents; D000911:Antibodies, Monoclonal; D014409:Tumor Necrosis Factor-alpha; D000069285:Infliximab